

Eduard Shantsila

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3558780/publications.pdf>

Version: 2024-02-01

194
papers

6,822
citations

87888

38
h-index

69250

77
g-index

200
all docs

200
docs citations

200
times ranked

10673
citing authors

#	ARTICLE	IF	CITATIONS
1	Altered cardiac and vascular stiffness in pregnancy after a hypertensive pregnancy. Journal of Human Hypertension, 2023, 37, 189-196.	2.2	4
2	Revisiting the diagnosis of "resistant hypertension": what should we do nowadays? Journal of Human Hypertension, 2022, 36, 337-340.	2.2	1
3	Monocytes are increased in pregnancy after gestational hypertensive disease. Scientific Reports, 2022, 12, .	3.3	0
4	Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant. Thrombosis Research, 2021, 197, 69-76.	1.7	1
5	Effects of antithrombotic drugs on the prothrombotic state in patients with atrial fibrillation: The west Birmingham atrial fibrillation project. Thrombosis Research, 2021, 200, 149-155.	1.7	4
6	Hypertension and sleep health: a multidimensional puzzle. Journal of Hypertension, 2021, 39, 600-601.	0.5	3
7	Anticoagulation versus placebo for heart failure in sinus rhythm. The Cochrane Library, 2021, 2021, CD003336.	2.8	6
8	Heart Failure With Sinus Rhythm: Does Anticoagulation Reduce Stroke at All?. Journal of Cardiac Failure, 2021, 27, 865-868.	1.7	1
9	Alterations in the Peripheral Circulation in Heart Failure. , 2020, , 201-213.e6.		0
10	Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial. Journal of the American Heart Association, 2020, 9, e016239.	3.7	20
11	Blood pressure targets in atrial fibrillation. European Heart Journal, 2020, 41, 2860-2862.	2.2	2
12	Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 13.	3.3	12
13	Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-42.	0.7	2
14	Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries. Circulation Journal, 2019, 83, 2434-2442.	1.6	6
15	Microparticles and cardiovascular diseases. Annals of Medicine, 2019, 51, 193-223.	3.8	36
16	Mon2 predicts poor outcome in <sc>ST</sc>-elevation myocardial infarction. Journal of Internal Medicine, 2019, 285, 301-316.	6.0	9
17	Risk Stratification in Atrial Fibrillation. , 2019, , 47-66.		0
18	Role of Monocytes in Heart Failure and Atrial Fibrillation. Journal of the American Heart Association, 2018, 7, .	3.7	72

#	ARTICLE	IF	CITATIONS
19	Nitrite circumvents platelet resistance to nitric oxide in patients with heart failure preserved ejection fraction and chronic atrial fibrillation. <i>Cardiovascular Research</i> , 2018, 114, 1313-1323.	3.8	12
20	Impact of Monocyte-platelet aggregates on human coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12911.	3.4	12
21	Predictors of diastolic dysfunction in ethnic groups: observations from the Hypertensive Cohort of The Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES). <i>Journal of Human Hypertension</i> , 2018, 32, 477-486.	2.2	4
22	Heart Failure and Stroke. <i>Current Heart Failure Reports</i> , 2018, 15, 287-296.	3.3	16
23	Prognostic implication of monocytes in atrial fibrillation: The West Birmingham Atrial Fibrillation Project. <i>PLoS ONE</i> , 2018, 13, e0200373.	2.5	3
24	Predictors of 5-year outcomes in malignant phase hypertension. <i>Journal of Hypertension</i> , 2017, 35, 2310-2314.	0.5	25
25	Renin-angiotensin blockade in atrial fibrillation: where are we now?. <i>Journal of Human Hypertension</i> , 2017, 31, 425-426.	2.2	6
26	Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. <i>EBioMedicine</i> , 2017, 18, 199-203.	6.1	18
27	Is echocardiography valid and reproducible in patients with atrial fibrillation? A systematic review. <i>Europace</i> , 2017, 19, 1427-1438.	1.7	48
28	Atrial Fibrillation and Hypertension. <i>Hypertension</i> , 2017, 70, 854-861.	2.7	100
29	Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1203-1213.	3.0	34
30	Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry. <i>Stroke</i> , 2017, 48, 2198-2205.	2.0	29
31	Current Understanding of Atherogenesis. <i>American Journal of Medicine</i> , 2017, 130, 268-282.	1.5	68
32	Renal dysfunction and diastolic impairment among British ethnic minorities with hypertension: the Ethnic-Echocardiographic Heart of England Screening Study. <i>Journal of Human Hypertension</i> , 2017, 31, 206-211.	2.2	1
33	Microvesicles in vascular homeostasis and diseases. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1296-1316.	3.4	193
34	Letters to the editor. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2017, 47, 205-207.	0.6	0
35	Stroke prevention in atrial fibrillation. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2017, 47, 13-23.	0.6	3
36	Role and analysis of monocyte subsets in cardiovascular disease. <i>Thrombosis and Haemostasis</i> , 2016, 116, 626-637.	3.4	113

#	ARTICLE	IF	CITATIONS
37	Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. <i>Heart</i> , 2016, 102, 1878-1882.	2.9	18
38	What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation?. <i>European Heart Journal Supplements</i> , 2016, 18, I18-I24.	0.1	2
39	Premature Cardiac Aging in South Asian Compared to Afro-Caribbean Subjects in a Community-Based Screening Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	4
40	Improved exercise tolerance in patients with Preserved Ejection fraction by Spironolactone on myocardial fibrosis in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. <i>BMJ Open</i> , 2016, 6, e012241.	1.9	14
41	Treatment of Atrial Fibrillation in Patients With Chronic Kidney Disease. <i>Chest</i> , 2016, 149, 891-892.	0.8	2
42	Use of non-vitamin K antagonist oral anticoagulants in patients with heart failure and atrial fibrillation: does concomitant kidney disease change our practice?. <i>European Journal of Heart Failure</i> , 2016, 18, 1172-1174.	7.1	1
43	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2033-2047.	1.8	4
44	Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 535-544.	2.1	21
45	Drug-drug interactions of non-vitamin K oral anticoagulants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1445-1461.	3.3	36
46	Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. <i>The Cochrane Library</i> , 2016, 9, CD003333.	2.8	11
47	Epidemiology and pathogenesis of diffuse obstructive coronary artery disease: the role of arterial stiffness, shear stress, monocyte subsets and circulating microparticles. <i>Annals of Medicine</i> , 2016, 48, 444-455.	3.8	25
48	Chronic Osteomyelitis and Atrial Fibrillation: Revisiting the Link Between Inflammation Burden and Arrhythmia. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1366-1368.	1.7	0
49	Symptom-to-door times in patients presenting with ST elevation myocardial infarction—do ethnic or gender differences exist?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 175-180.	0.5	7
50	Endothelial Progenitors and Blood Microparticles: Are They Relevant to Heart Failure With Preserved Ejection Fraction?. <i>EBioMedicine</i> , 2016, 4, 5-6.	6.1	7
51	Emerging Tools for Stroke Prevention in Atrial Fibrillation. <i>EBioMedicine</i> , 2016, 4, 26-39.	6.1	15
52	Atrial fibrillation and its complications: a focus on identifying risk factors and risk stratification. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 88-89.	3.0	3
53	Preventing Thrombosis to Improve Outcomes in Heart Failure Patients. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 386-392.	3.1	6
54	Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention. <i>F1000Research</i> , 2016, 5, 2887.	1.6	5

#	ARTICLE	IF	CITATIONS
55	Optimising stroke prevention in patients with atrial fibrillation. <i>British Journal of General Practice</i> , 2015, 65, 117-117.	1.4	3
56	Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. <i>British Journal of General Practice</i> , 2015, 65, e16-e23.	1.4	37
57	Safety and efficacy of abciximab in older adults undergoing percutaneous coronary intervention. <i>International Journal of Clinical Practice</i> , 2015, 69, 1334-1340.	1.7	0
58	Stroke in atrial fibrillation and improving the identification of "high-risk" patients: the crossroads of immunity and thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1968-1970.	3.8	11
59	124...South Asian Ethnicity is Independently Related to Diastolic Function in Hypertension: Abstract 124 Table 1. <i>Heart</i> , 2015, 101, A71-A72.	2.9	0
60	Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. <i>International Journal of Clinical Practice</i> , 2015, 69, 840-845.	1.7	25
61	CD4+ T cell surface alpha enolase is lower in older adults. <i>Mechanisms of Ageing and Development</i> , 2015, 152, 56-62.	4.6	2
62	Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. <i>Age and Ageing</i> , 2015, 44, 874-878.	1.6	57
63	Free Light Chains in patients with acute coronary syndromes: Relationships to inflammation and renal function. <i>International Journal of Cardiology</i> , 2015, 185, 322-327.	1.7	7
64	Ethnic differences in the diurnal variation of symptom onset time for acute ST elevation myocardial infarction " An observational cohort study. <i>International Journal of Cardiology</i> , 2015, 187, 414-416.	1.7	1
65	Small-size Microparticles as Indicators of Acute Decompensated State in Ischemic Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 951-958.	0.6	8
66	Simultaneous computerised activation of the primary percutaneous coronary intervention pathway reduces out-of-hours door-to-balloon time but not mortality. <i>International Journal of Cardiology</i> , 2015, 186, 226-230.	1.7	0
67	Cardiac Fibrosis in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 943-959.	2.8	427
68	CD36 expression and lipid metabolism following an oral glucose challenge in South Asians. <i>World Journal of Diabetes</i> , 2015, 6, 983.	3.5	3
69	Circulating microparticles: challenges and perspectives of flow cytometric assessment. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1009-1014.	3.4	55
70	The membrane expression of P-selectin, but not monocyte-platelet aggregates, is influenced by variability in response to aspirin in patients with coronary artery disease. <i>Platelets</i> , 2014, 25, 142-143.	2.3	1
71	Monocytes circulate in constant reversible interaction with platelets in a [Ca ²⁺]-dependent manner. <i>Platelets</i> , 2014, 25, 197-201.	2.3	8
72	Expression of monocyte subsets and angiogenic markers in relation to carotid plaque neovascularization in patients with pre-existing coronary artery disease and carotid stenosis. <i>Annals of Medicine</i> , 2014, 46, 530-538.	3.8	35

#	ARTICLE	IF	CITATIONS
73	Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease. Expert Opinion on Therapeutic Targets, 2014, 18, 43-53.	3.4	21
74	Monocyte subsets in coronary artery disease and their associations with markers of inflammation and fibrinolysis. Atherosclerosis, 2014, 234, 4-10.	0.8	49
75	Anticoagulation versus placebo for heart failure in sinus rhythm. The Cochrane Library, 2014, , CD003336.	2.8	31
76	The Role of Monocytes in Angiogenesis and Atherosclerosis. Journal of the American College of Cardiology, 2014, 63, 1-11.	2.8	347
77	Small size platelet microparticles trigger platelet and monocyte functionality and modulate thrombogenesis via P-selectin. British Journal of Haematology, 2014, 166, 571-580.	2.5	24
78	Free Light Chains in Patients With Acute Heart Failure Secondary to Atherosclerotic Coronary Artery Disease. American Journal of Cardiology, 2014, 114, 1243-1248.	1.6	9
79	Use of Novel Oral Anticoagulants in Patients With Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 285.	0.9	4
80	Thrombotic Complications in Heart Failure. Circulation, 2014, 130, 387-389.	1.6	26
81	Ventricular-arterial coupling in obstructive sleep apnea. Journal of the American Society of Hypertension, 2014, 8, 624-629.	2.3	6
82	Ultrasound-assisted thrombolysis with streptokinase improves thrombus resolution with minimal distal embolisation. Journal of Thrombosis and Thrombolysis, 2013, 36, 263-270.	2.1	4
83	<sc>TLR</sc>4 expression on monocyte subsets in myocardial infarction. Journal of Internal Medicine, 2013, 273, 294-305.	6.0	21
84	The immunological axis in heart failure: importance of the leukocyte differential. Heart Failure Reviews, 2013, 18, 835-845.	3.9	54
85	Monocytes in Coronary Artery Disease and Atherosclerosis. Journal of the American College of Cardiology, 2013, 62, 1541-1551.	2.8	316
86	The effect of statin therapy withdrawal on monocyte subsets. European Journal of Clinical Investigation, 2013, 43, 1307-1313.	3.4	14
87	Stroke Prevention in Atrial Fibrillation in Heart Failure. Heart Failure Clinics, 2013, 9, 427-435.	2.1	2
88	A comprehensive assessment of cardiac structure and function in patients with treated malignant phase hypertension: The West Birmingham Malignant Hypertension project. International Journal of Cardiology, 2013, 167, 67-72.	1.7	10
89	<sc>CD</sc>14++<sc>CD</sc>16+ monocytes in patients with acute ischaemic heart failure. European Journal of Clinical Investigation, 2013, 43, 121-130.	3.4	70
90	Left Ventricular Fibrosis in Atrial Fibrillation. American Journal of Cardiology, 2013, 111, 996-1001.	1.6	41

#	ARTICLE	IF	CITATIONS
91	Small-size circulating microparticles in acute coronary syndromes: Relevance to fibrinolytic status, reparative markers and outcomes. <i>Atherosclerosis</i> , 2013, 227, 313-322.	0.8	87
92	Pharmacokinetic considerations for antithrombotic therapies in stroke. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1335-1347.	3.3	4
93	Increased Formation of Monocyte-Platelet Aggregates in Ischemic Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 127-135.	3.9	55
94	Evaluation of Carotid Plaque Neovascularization Using Contrast Ultrasound. <i>Angiology</i> , 2013, 64, 447-450.	1.8	14
95	Recent advances in management of atrial fibrillation in patients with heart failure. <i>Current Opinion in Cardiology</i> , 2013, 28, 197-208.	1.8	5
96	Receptors to interleukin-6 and adhesion molecules on circulating monocyte subsets in acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2013, 110, 340-348.	3.4	7
97	Increased expression of cell adhesion molecule receptors on monocyte subsets in ischaemic heart failure. <i>Thrombosis and Haemostasis</i> , 2013, 110, 92-100.	3.4	20
98	CXCR4 positive and angiogenic monocytes in myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2013, 109, 255-262.	3.4	21
99	Vitamin K Antagonists and Their Limitations. , 2013, , 33-40.		1
100	New Oral Anticoagulants. , 2013, , 53-86.		0
101	Common Clinical Indications for Anticoagulation. , 2013, , 7-31.		0
102	A contemporary view on endothelial function in heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 873-881.	7.1	65
103	Vascular ventricular coupling in patients with malignant phase hypertension: the West Birmingham malignant hypertension project. <i>Hypertension Research</i> , 2012, 35, 725-728.	2.7	3
104	Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders. <i>Current Pharmaceutical Design</i> , 2012, 18, 840-849.	1.9	7
105	A contemporary viewpoint on "aspirin resistance". <i>Annals of Medicine</i> , 2012, 44, 773-783.	3.8	20
106	An innovative flow cytometric approach for small-size platelet microparticles: Influence of calcium. <i>Thrombosis and Haemostasis</i> , 2012, 108, 373-383.	3.4	31
107	Blood leukocytes in heart failure with preserved ejection fraction: Impact on prognosis. <i>International Journal of Cardiology</i> , 2012, 155, 337-338.	1.7	14
108	Fibrinolytic status in acute coronary syndromes: Evidence of differences in relation to clinical features and pathophysiological pathways. <i>Thrombosis and Haemostasis</i> , 2012, 108, 32-40.	3.4	17

#	ARTICLE	IF	CITATIONS
109	The CD14 ⁺⁺ CD16 ⁺ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1231-1241.	3.8	164
110	Monocyte-derived and CD34 ⁺ /KDR ⁺ endothelial progenitor cells in heart failure. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1252-1261.	3.8	16
111	The effects of exercise and diurnal variation on monocyte subsets and monocyte-platelet aggregates. <i>European Journal of Clinical Investigation</i> , 2012, 42, 832-839.	3.4	34
112	Antithrombotic therapy after percutaneous coronary intervention in anticoagulated patients: a fine balance between thrombosis and bleeding. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011, 5, 5-9.	2.1	4
113	The nuclear factor κ B pathway in atherosclerosis: A potential therapeutic target for atherothrombotic vascular disease. <i>Thrombosis Research</i> , 2011, 128, 117-123.	1.7	178
114	The Quest for New Anticoagulants: From Clinical Development to Clinical Practice. <i>Cardiovascular Therapeutics</i> , 2011, 29, e12-e22.	2.5	10
115	Atorvastatin and its collateral effects on microparticles. <i>Thrombosis and Haemostasis</i> , 2011, 106, 185-186.	3.4	5
116	Monocytes: Possible mediators of benefits and harms from physical activity?. <i>Thrombosis and Haemostasis</i> , 2011, 105, 387-389.	3.4	1
117	Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1056-1066.	3.8	147
118	Systolic heart failure in South Asians. <i>International Journal of Clinical Practice</i> , 2011, 65, 1274-1282.	1.7	10
119	Platelet reactivity in prolonged stress disorders? A link with cardiovascular disease?. <i>Psychoneuroendocrinology</i> , 2011, 36, 159-160.	2.7	2
120	The Risk of Thromboembolism in Heart Failure: Does It Merit Anticoagulation Therapy?. <i>American Journal of Cardiology</i> , 2011, 107, 558-560.	1.6	8
121	Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. <i>Basic Research in Cardiology</i> , 2011, 106, 911-923.	5.9	80
122	Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: A comparison with plasma vascular markers. <i>Prostate</i> , 2011, 71, 1047-1053.	2.3	22
123	The role of monocytes and inflammation in the pathophysiology of heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 1161-1171.	7.1	162
124	Persistent Macrovascular and Microvascular Dysfunction in Patients With Malignant Hypertension. <i>Hypertension</i> , 2011, 57, 490-496.	2.7	47
125	The CD40-CD40L system in cardiovascular disease. <i>Annals of Medicine</i> , 2011, 43, 331-340.	3.8	107
126	Ethnic Differences in Macrovascular and Microvascular Function in Systolic Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 754-762.	3.9	26

#	ARTICLE	IF	CITATIONS
127	Myocardial Perfusion by Myocardial Contrast Echocardiography and Endothelial Dysfunction in Obstructive Sleep Apnea. <i>Hypertension</i> , 2011, 58, 417-424.	2.7	50
128	102 Ethnic differences in endothelial function in chronic heart failure. <i>Heart</i> , 2011, 97, A59-A59.	2.9	0
129	Endothelial dysfunction and diurnal variation of blood pressure: night secrets of arterial hypertension?. <i>Journal of Human Hypertension</i> , 2011, 25, 653-655.	2.2	1
130	Soluble Fms-Like Tyrosine Kinase-1. <i>Circulation Journal</i> , 2010, 74, 2064-2065.	1.6	2
131	Aspirin—A Drug Whose Time Has Gone?. <i>American Journal of Cardiology</i> , 2010, 105, 577-578.	1.6	1
132	Endothelial progenitor cells: what use for the cardiologist?. <i>Journal of Angiogenesis Research</i> , 2010, 2, 6.	2.9	32
133	Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2358-2368.	3.8	143
134	Novel oral anticoagulants: the potential relegation of vitamin K antagonists in clinical practice. <i>International Journal of Clinical Practice</i> , 2010, 64, 835-838.	1.7	6
135	Circulating progenitor cells in patients with atrial fibrillation and their relation with serum markers of inflammation and angiogenesis. <i>Thrombosis and Haemostasis</i> , 2010, 104, 327-334.	3.4	5
136	The effects of exercise stress testing, diurnal variation and temporal decline on circulating progenitor cells. <i>Thrombosis and Haemostasis</i> , 2010, 103, 419-424.	3.4	7
137	Circulating monocytes and atherogenesis: From animal experiments to human studies. <i>Thrombosis and Haemostasis</i> , 2010, 104, 191-193.	3.4	5
138	Coronary Atherosclerosis in Rheumatoid Arthritis: Could Endothelial Progenitor Cells Be the Missing Link?. <i>Journal of Rheumatology</i> , 2010, 37, 479-481.	2.0	4
139	Blockade of the renin-angiotensin system in atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2010, 7, 428-430.	13.7	6
140	Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair?. <i>Cardiovascular Research</i> , 2010, 85, 649-660.	3.8	66
141	Role of Ticagrelor in Clopidogrel Nonresponders: Resistance Is Futile?. <i>Circulation</i> , 2010, 121, 1169-1171.	1.6	21
142	Arterial stiffening in hypertension: beyond blood pressure levels. <i>Journal of Human Hypertension</i> , 2010, 24, 303-305.	2.2	6
143	Percutaneous Coronary Intervention in Anticoagulated Patients and Balancing the Risk of Stroke and Bleeding. <i>Chest</i> , 2010, 138, 771-774.	0.8	1
144	The role of monocytes in atherosclerotic coronary artery disease. <i>Annals of Medicine</i> , 2010, 42, 394-403.	3.8	108

#	ARTICLE	IF	CITATIONS
145	Malignant Hypertension: A Rare Problem or is it Underdiagnosed?. <i>Current Vascular Pharmacology</i> , 2010, 8, 775-779.	1.7	15
146	The endothelium and thrombotic risk in heart failure. <i>Thrombosis and Haemostasis</i> , 2009, 102, 185-187.	3.4	30
147	Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation". <i>Thrombosis and Haemostasis</i> , 2009, 102, 914-915.	3.4	15
148	The role of monocytes in thrombotic disorders. <i>Thrombosis and Haemostasis</i> , 2009, 102, 916-924.	3.4	123
149	Monocytes in Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1433-1438.	2.4	57
150	Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand factor and circulating endothelial cells, following acute myocardial infarction. <i>Annals of Medicine</i> , 2009, 41, 608-618.	3.8	6
151	Angiopoietins and Preeclampsia: New Perspectives in the Quest for Markers. <i>American Journal of Hypertension</i> , 2009, 22, 820-820.	2.0	4
152	Heparin-Induced Thrombocytopenia: Response. <i>Chest</i> , 2009, 136, 1704-1705.	0.8	1
153	Microparticles and Arterial Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 488-496.	2.7	42
154	Endothelial microparticles: a universal marker of vascular health?. <i>Journal of Human Hypertension</i> , 2009, 23, 359-361.	2.2	20
155	Targeting the arterial wall, but what is the target?. <i>Journal of Human Hypertension</i> , 2009, 23, 1-3.	2.2	4
156	Vascular Imaging as a Cardiovascular Risk Stratification Tool in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 2141-2143.	2.0	1
157	Endothelial function and endothelial progenitors: possible mediators of the benefits from physical exercise?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 401-403.	2.8	5
158	Systemic inflammation as a driver of vascular calcification: a proof of concept. <i>Journal of Internal Medicine</i> , 2009, 266, 453-456.	6.0	12
159	AZD6140 and bleeding: towards safer antiplatelet therapy?. <i>International Journal of Clinical Practice</i> , 2009, 63, 537-539.	1.7	1
160	Novel oral anticoagulants. <i>International Journal of Clinical Practice</i> , 2009, 63, 630-641.	1.7	29
161	New antiplatelet drugs: beyond aspirin and clopidogrel. <i>International Journal of Clinical Practice</i> , 2009, 63, 776-789.	1.7	18
162	Variability of response to antiplatelet therapy: what should we do next?. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 19-22.	1.9	1

#	ARTICLE	IF	CITATIONS
163	Antithrombotic therapy for heart failure in sinus rhythm. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 705-717.	1.9	8
164	Evidence guided antiplatelet treatment: Time to move from bench to bedside. <i>Thrombosis Research</i> , 2009, 124, 649-650.	1.7	1
165	Monocyte Diversity in Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2009, 54, 139-142.	2.8	28
166	Fondaparinux: an overview. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 577-585.	1.5	13
167	New Anticoagulants for the Prevention of Deep Venous Thrombosis. <i>Pharmacoeconomics</i> , 2009, 27, 793-795.	3.3	3
168	Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. <i>Lancet, The</i> , 2009, 373, 155-166.	13.7	873
169	Mechanisms of thrombogenesis in atrial fibrillation – Authors' reply. <i>Lancet, The</i> , 2009, 373, 1006-1007.	13.7	10
170	Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2009, 135, 1651-1664.	0.8	124
171	Angiopietins in arterial hypertension: a mechanism of adaptation or a target for treatment?. <i>Journal of Hypertension</i> , 2009, 27, 1524-1526.	0.5	2
172	Rivaroxaban, a new oral factor Xa inhibitor, provides new data on anticoagulation. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 187-189.	0.2	1
173	Circulating endothelial cells: from bench to clinical practice. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 865-868.	3.8	20
174	Circulating endothelial cells in health and disease: how do we best quantify them?. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1021-1024.	3.8	6
175	'Aspirin resistance' or treatment non-compliance: Which is to blame for cardiovascular complications?. <i>Journal of Translational Medicine</i> , 2008, 6, 47.	4.4	26
176	Cardioversion and remodelling in atrial fibrillation: Insights beyond the prothrombotic state. <i>Thrombosis Research</i> , 2008, 121, 443-445.	1.7	1
177	Statins and inflammation: Reciprocal effectors to endothelial progenitors?. <i>Thrombosis Research</i> , 2008, 123, 1-4.	1.7	5
178	Circulating endothelial cells and rheumatoid arthritis: relationship with plasma markers of endothelial damage/dysfunction. <i>Rheumatology</i> , 2008, 48, 285-288.	1.9	22
179	The search for new anticoagulants: dabigatran etexilate. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 793-796.	0.2	4
180	Predicting thrombotic events: Creating a complex approach for a complex condition. <i>Thrombosis and Haemostasis</i> , 2008, 100, 962-964.	3.4	5

#	ARTICLE	IF	CITATIONS
181	Beyond glucose levels in diabetic patients with coronary artery disease: Platelet activity and non-responsiveness to antiplatelet therapy. <i>Thrombosis and Haemostasis</i> , 2008, 100, 07-08.	3.4	2
182	Antioxidant protection: yet another function of endothelial progenitor cells?. <i>Journal of Human Hypertension</i> , 2007, 21, 343-346.	2.2	11
183	Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. <i>Europace</i> , 2007, 9, iv37-iv44.	1.7	41
184	Aspirin resistance: What, why and when?. <i>Thrombosis Research</i> , 2007, 119, 551-554.	1.7	26
185	Fibrin D-dimer levels and thromboembolic events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2007, 120, 123-124.	1.7	5
186	Endothelial colony forming units: Are they a reliable marker of endothelial progenitor cell numbers?. <i>Annals of Medicine</i> , 2007, 39, 474-479.	3.8	25
187	Endothelial Progenitor Cells in Cardiovascular Disorders. <i>Journal of the American College of Cardiology</i> , 2007, 49, 741-752.	2.8	390
188	Standardization of circulating endothelial cell enumeration by the use of human umbilical vein endothelial cells. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 870-872.	3.8	10
189	Anticoagulation for Stroke Prevention. <i>Pharmacoeconomics</i> , 2006, 24, 1035-1038.	3.3	0
190	Pharmacotherapy for atrial fibrillation: is rhythm control achievable?. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1105-1107.	1.8	0
191	Atrial fibrillation post-cardiac surgery: changing perspectives. <i>Current Medical Research and Opinion</i> , 2006, 22, 1437-1441.	1.9	41
192	Anticoagulation for stroke prevention in atrial fibrillation: is gender important?The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2006, 27, 1893-1894.	2.2	16
193	Therapy for atrial fibrillation: new challenges. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 445-448.	0.2	0
194	Laboratory investigation of platelets. , 2001, , 124-146.		2